Danazol‐induced hepatocellular carcinoma

In: QJM: An International Journal of Medicine · 2003 · vol. 96(4) , pp. 317 · doi:10.1093/qjmed/hcg050 · PMID:12651980 · W2152912347
letter OA: bronze CC0 ⤵ 3 in-corpus citations
AI-generated summary by gemini-2.5-flash-lite, 2026-06-08

This case report describes a 37-year-old female with ITP treated with danazol, a drug known for its hepatological side-effects, who subsequently developed hepatocellular carcinoma.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Sir, Danazol, an inhibitor of pituitary gonadotropin with weak androgenic effects, is currently used in the treatment of endometriosis, hereditary angio‐oedema, systemic lupus erythematosus, and idiopathic thrombocytopenic purpura (ITP). Its hepatological side‐effects have been well documented. These include reversible elevations of serum aminotransferase values,1 cholestatic hepatitis,2 hepatic peliosis3 and hepatocellular adenomas.4 Only a few cases of danazol‐associated hepatocellular carcinoma (HCC) have been described.5–,7 We report a new case. A 37‐year‐old female with ITP refractory to corticotherapy, intravenous immunoglobulins, vincristine and splenectomy, was treated with 600 mg danazol daily in March 1995. Danazol induced a dramatic clinical and biological response, settling thrombocytes counts at 40×109 …

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (11)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-10T12:02:09.231096+00:00
License: CC0 · commercial use OK